Bellicum raises $20M in Series B financing Bellicum Pharmaceuticals.

Results from a recently available proof-of-concept research with CaspaCIDe technology in individuals with severe leukemia were released in the brand new England Journal of Medication showing rapid and full reversal of GVHD. ‘Bellicum shows that CID technology can control built cells in the body, with profound advantage in a number of clinical settings potentially,’ commented James Brown, Supervisor of AVG Ventures. ‘The management group has achieved this with a higher degree of capital effectiveness, and is currently well positioned to progress its multi-item portfolio through mid-stage trials.’.. Bellicum raises $20M in Series B financing Bellicum Pharmaceuticals, Inc.Licensed from medwireNews with authorization from Springer Health care Ltd. All privileges reserved. Neither of the parties endorse or suggest any commercial products, services, or equipment.

Bacterial pathogens require vitamin B6 biosynthesis enzymes for virulence: Study Scientists have got determined that Helicobacter pylori, the bacterium that triggers peptic ulcers plus some forms of stomach malignancy, requires the supplement B6 to establish and keep maintaining chronic infection, according to analyze published this total week in the web journal mBio. This finding, combined with the identification of the enzyme the microbe needs to work with the vitamin, may lead to the development of a completely new course of antibiotics.